Rubicon Research is a pharmaceutical player
developing, manufacturing, and commercialization of differentiated formulations,
with a primary emphasis on regulated markets, particularly the United States.
The company derives most of its revenue from the US market,
which accounted for 99.5% of total revenue in Q1 FY26. Of this, 75.15% of
product sales were through its own distribution channel, while 24.85% were via
third-party partners.
As of March 31, 2025, the portfolio comprised 66
commercialized products. In FY25, nine of its products each held over 25% share
in value in the US market. By June 2025, its commercialization rate in the US
reached 86.4%, with 70 commercialized products out of 81 active Abbreviated New
Drug Application ...
More News
-
(30-Oct-25 13:45)
Lenskart Solutions
-
(28-Oct-25 18:11)
Studds Accessories
-
(27-Oct-25 15:39)
Orkla India
-
(14-Oct-25 09:28)
Midwest
|
|